Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (Note: Request metadata listed "Bio Green Med Solution, Inc.", but the filing text identifies the registrant as Cyclacel Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2025
Reporting Period: Event-specific report dated July 28, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure amendments rather than financial performance.
Material Changes
Amendment to Series F Convertible Preferred Stock:
- The Company filed an Amended and Restated Certificate of Designation for its Series F Convertible Preferred Stock with the Delaware Secretary of State on July 28, 2025.
- Removal of Ownership Limitation: The amendment removes the "Series F Ownership Limitation," which previously restricted conversion and voting rights to prevent the holder from exceeding the lower of (i) the Nasdaq Capital Market threshold for stockholder approval or (ii) 4.99% of outstanding common stock prior to the original issue date.
- Effect: Shares of Series F Convertible Preferred Stock may now be converted and voted without regard to the previous ownership cap.
- Approval: The change was approved by the Board of Directors and the majority stockholder, as disclosed in a Schedule 14C filed on July 7, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors beyond the structural change to the preferred stock. The document notes that no other changes were made to the Series F Certificate of Designation.
Investor Verification Checklist
- Verify the impact of removing the 4.99% ownership limitation on the Company's common stock dilution and voting control dynamics.
- Review the Definitive Information Statement on Schedule 14C (filed July 7, 2025) for details on the majority stockholder's approval and the rationale for the amendment.
- Confirm the current conversion status of the Series F Convertible Preferred Stock and any potential immediate conversion activity following the removal of the cap.
- Check for any subsequent filings regarding the actual conversion of Series F shares into common stock.